Detalhe da pesquisa
1.
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
EClinicalMedicine
; 63: 102160, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37649806
2.
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Lancet Reg Health Am
; 21: 100497, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37192953
3.
Enemas de factor de crecimiento epidérmico para inducir la remisión de la colitis ulcerosa izquierda / Epidermal growth factor enemas for induction of remission in left-sided ulcerative colitis
Rev. cuba. farm
; 47(1): 67-76, ene.-mar. 2013.
Artigo
em Inglês
| LILACS | ID: lil-674112